The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Crenolanib plus 7+3 chemotherapy in adults with newly diagnosed FLT3-mutated AML.
In this video, Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, presents long-term results of a Phase II study evaluating crenolanib, a potent FLT3 inhibitor, in patients with new diagnosed FLT3-mutated acute myeloid leukemia (AML). In combination with 7+3 induction and consolidation, crenolanib demonstrates high response rates in this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
